Pharmacology of Anxiolytics and How it Relates to Neurobiology of Anxiety

Introduction to this topic

Professor John Atack
Professor of Molecular Pharmacology & Director of the Translational Drug Discovery Group, University of Sussex

Updated: Wednesday, 4th September 2019
Last Checked: Wednesday, 4th September 2019 Current

Supporting Files

Supporting files for this topic are available if you have a current CPD subscription.

This topic explores the neurobiology of anxiety disorders, drawing on insights from pre-clinical and clinical studies. The role of serotonin, noradrenaline and GABA in mechanisms underlying anxiety symptoms and in the response to antidepressant and anxiolytic drugs is emphasised. Potential new targets for anxiolytic drugs are discussed.

Back to Anxiety Disorders

NB you need to be logged in and your subscription must be up to date in order to view the presentations below

Sections in this Topic

Play the video for Section

The Neuroanatomy of Anxiety Disorders

Duration: 05m 06s
No. of slides: 4 - View Slide List

Play the video for Section

The Neurochemistry of Anxiety Disorders

Duration: 07m 30s
No. of slides: 6 - View Slide List

Play the video for Section

Animal models of anxiety

Duration: 06m 01s
No. of slides: 4 - View Slide List

Play the video for Section

Novel Anxiolytics - Focus on Next-Generation GABAA Receptor Modulators

Duration: 11m 17s
No. of slides: 7 - View Slide List